EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu, Peter V Balint, Heidi Bertheussen, Wolf-Henning Boehncke, Gerd R Burmester, Juan D Canete, Nemanja S Damjanov, Tue Wenzel Kragstrup, Tore K Kvien, Robert B M Landewé, Rik Jozef Urbain LoriesHelena Marzo-Ortega, Denis Poddubnyy, Santiago Andres Rodrigues Manica, Georg Schett, Douglas J Veale, Filip E Van den Bosch, Désirée van der Heijde, Josef S Smolen

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

707 Citationer (Scopus)
66 Downloads (Pure)

Abstract

OBJECTIVE: To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA).

METHODS: According to the EULAR standardised operating procedures, a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019. Levels of evidence and strengths of recommendations were determined.

RESULTS: The updated recommendations comprise 6 overarching principles and 12 recommendations. The overarching principles address the nature of PsA and diversity of both musculoskeletal and non-musculoskeletal manifestations; the need for collaborative management and shared decision-making is highlighted. The recommendations provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs and local glucocorticoid injections are proposed as initial therapy; for patients with arthritis and poor prognostic factors, such as polyarthritis or monoarthritis/oligoarthritis accompanied by factors such as dactylitis or joint damage, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumour necrosis factor (TNF), interleukin (IL)-17A or IL-12/23 should be initiated, taking into account skin involvement if relevant. If axial disease predominates, a TNF inhibitor or IL-17A inhibitor should be started as first-line disease-modifying antirheumatic drug. Use of Janus kinase inhibitors is addressed primarily after bDMARD failure. Phosphodiesterase-4 inhibition is proposed for patients in whom these other drugs are inappropriate, generally in the context of mild disease. Drug switches and tapering in sustained remission are addressed.

CONCLUSION: These recommendations provide stakeholders with an updated consensus on the pharmacological management of PsA, based on a combination of evidence and expert opinion.

OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
Vol/bind79
Nummer6
Sider (fra-til)700-712
Antal sider13
ISSN0003-4967
DOI
StatusUdgivet - 2020

Fingeraftryk

Dyk ned i forskningsemnerne om 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update'. Sammen danner de et unikt fingeraftryk.

Citationsformater